pentoxifylline has been researched along with Peripheral Vascular Diseases in 42 studies
Peripheral Vascular Diseases: Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 9.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 8.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 8.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 5.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 4.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 4.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| " For this study, 20 PAD patients were assigned to take either pentoxifylline (n=11) or cilostazol (n=9), the two FDA-approved pharmacological therapies used to treat intermittent claudication symptoms." | 3.76 | Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes. ( Huisinga, JM; Johanning, JM; Pipinos, II; Stergiou, N, 2010) |
| " Compliance with treatment and occurrence of adverse events were constantly monitored; systemic tolerability was evaluated through the use of routine haematological and haematochemical tests." | 2.68 | Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease. ( Shustov, SB, 1997) |
| "Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated." | 2.45 | Pharmacologic therapy for intermittent claudication. ( Dobesh, PP; Persson, EL; Stacy, ZA, 2009) |
| "Pyoderma gangrenosum is most commonly treated with immunosuppressants or anti-inflammatory agents and is often worsened by surgical procedures due to the presence of pathergy." | 1.48 | Improvement of Ulcerations in Treatment-Resistant Chronic Scarring in a Patient with Pyoderma Gangrenosum After Improving Vascular Insufficiency, Gently Removing Necrotic Debris, and Decreasing Wound Fluid. ( Gordon, C; Hizon, BJ; Mota, JA; Nahm, WJ; Rojas, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (42.86) | 18.2507 |
| 2000's | 12 (28.57) | 29.6817 |
| 2010's | 11 (26.19) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, T | 1 |
| Forster, RB | 1 |
| Cleanthis, M | 2 |
| Mikhailidis, DP | 2 |
| Stansby, G | 4 |
| Stewart, M | 2 |
| Vietto, V | 1 |
| Franco, JV | 1 |
| Saenz, V | 1 |
| Cytryn, D | 1 |
| Chas, J | 1 |
| Ciapponi, A | 1 |
| Nahm, WJ | 1 |
| Mota, JA | 1 |
| Rojas, S | 1 |
| Hizon, BJ | 1 |
| Gordon, C | 1 |
| Słoczyńska, K | 1 |
| Kózka, M | 1 |
| Pękala, E | 1 |
| Marchewka, A | 1 |
| Marona, H | 1 |
| Roset, PN | 1 |
| Stevens, JW | 2 |
| Simpson, E | 2 |
| Harnan, S | 2 |
| Squires, H | 2 |
| Meng, Y | 2 |
| Thomas, S | 2 |
| Michaels, J | 2 |
| Bedenis, R | 1 |
| Robless, P | 1 |
| Dobesh, PP | 1 |
| Stacy, ZA | 1 |
| Persson, EL | 1 |
| Huisinga, JM | 2 |
| Pipinos, II | 2 |
| Johanning, JM | 2 |
| Stergiou, N | 2 |
| Olin, JW | 1 |
| Sealove, BA | 1 |
| Sheck, L | 1 |
| Bachoo, P | 2 |
| Koshkin, VM | 1 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Kashyap, VS | 1 |
| Kim, DH | 1 |
| Regensteiner, JG | 3 |
| Stewart, KJ | 1 |
| Creager, MA | 1 |
| Pande, RL | 1 |
| Hiatt, WR | 3 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Scheffler, P | 1 |
| de la Hamette, D | 1 |
| Gross, J | 1 |
| Mueller, H | 1 |
| Schieffer, H | 1 |
| Campbell, RK | 1 |
| Opler, LA | 1 |
| Gorman, JM | 1 |
| Isner, JM | 1 |
| Rosenfield, K | 1 |
| Frampton, JE | 1 |
| Brogden, RN | 1 |
| Vadiei, K | 1 |
| Tucker, SD | 1 |
| Lopez-Berestein, G | 1 |
| Wasan, KM | 1 |
| Ciocon, JO | 1 |
| Galindo-Ciocon, D | 1 |
| Galindo, DJ | 1 |
| Kohout, J | 1 |
| Hůzl, F | 1 |
| Bejcková, H | 1 |
| Soukupová, K | 1 |
| Labs, KH | 1 |
| Labs, R | 1 |
| Rössner, M | 1 |
| Shustov, SB | 1 |
| Langley, PC | 1 |
| Coons, SJ | 1 |
| Dosquet, C | 1 |
| Weill, D | 1 |
| Wautier, JL | 1 |
| Cummings, DM | 1 |
| Ballas, SK | 1 |
| Ellison, MJ | 1 |
| Ernst, E | 1 |
| Kollár, L | 1 |
| Resch, KL | 1 |
| Elliot, EC | 1 |
| Kollarits, CR | 1 |
| Ciuffetti, G | 1 |
| Mercuri, M | 1 |
| Ott, C | 1 |
| Lombardini, R | 1 |
| Paltriccia, R | 1 |
| Lupattelli, G | 1 |
| Santambrogio, L | 1 |
| Mannarino, E | 1 |
| Poflee, VW | 1 |
| Gupta, OP | 1 |
| Jain, AP | 1 |
| Jajoo, UN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)[NCT03883412] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | ||
| The THOR IDE Study[NCT05916950] | 155 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | |||
| Multicenter, Randomized, Dose-search, Parallel, Double-blind, and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Intramuscular Administration of Allogeneic Adipose Tissue Adult Mesenchymal Stem Cells in Diabetic Patients With Cri[NCT04466007] | Phase 2 | 90 participants (Anticipated) | Interventional | 2021-01-11 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for pentoxifylline and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Cilostazol for intermittent claudication.
Topics: Aged; Bias; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pento | 2021 |
Prostanoids for critical limb ischaemia.
Topics: Alprostadil; Amputation, Surgical; Epoprostenol; Humans; Iloprost; Ischemia; Leg; Leg Ulcer; Nafrony | 2018 |
Cilostazol for intermittent claudication.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pentoxifyll | 2014 |
Pharmacologic therapy for intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Dietary Supplements; Drugs, Investigational; Exercise Therapy; | 2009 |
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pain; Pentoxifylline; Peripheral Vascular D | 2012 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Exercise; Humans; Intermittent Claudication; Pentoxifylline; Perip | 2003 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Exercise; Humans; Pentoxifylline; Peripheral Vascular Diseases; Pl | 2004 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Coronary Artery Bypass; Exercise; Humans; Pentoxifylline; Peripher | 2004 |
[The use of pentoxyphylline in the treatment of patients with chronic obliterative diseases of lower limb arteries].
Topics: Administration, Oral; Arterial Occlusive Diseases; Blood Cells; Chronic Disease; Controlled Clinical | 2005 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
Established and evolving medical therapies for claudication in patients with peripheral arterial disease.
Topics: Ankle; Arterial Occlusive Diseases; Blood Pressure; Brachial Artery; Cilostazol; Exercise Test; Exer | 2006 |
Clinical update on pentoxifylline therapy for diabetes-induced peripheral vascular disease.
Topics: Clinical Trials as Topic; Diabetes Complications; Diabetic Angiopathies; Diabetic Foot; Female; Huma | 1993 |
Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Laser-Assisted; Angioplasty, Laser; Arterial Occlusive D | 1993 |
Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Laser-Assisted; Angioplasty, Laser; Arterial Occlusive D | 1993 |
Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Laser-Assisted; Angioplasty, Laser; Arterial Occlusive D | 1993 |
Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Laser-Assisted; Angioplasty, Laser; Arterial Occlusive D | 1993 |
Nonsurgical management of peripheral arterial disease.
Topics: Activities of Daily Living; Aged; Angioplasty; Arterial Occlusive Diseases; Clinical Protocols; Exer | 1993 |
Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.
Topics: Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Pentoxifylline; Peripheral Vascul | 1995 |
Clinical experience with pentoxifylline.
Topics: Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Vasodilator Agents | 1997 |
Peripheral vascular disorders. A pharmacoeconomic and quality-of-life review.
Topics: Cost-Benefit Analysis; Humans; Pentoxifylline; Peripheral Vascular Diseases; Quality of Life | 1997 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
Molecular mechanism of blood monocyte adhesion to vascular endothelial cells.
Topics: Cell Adhesion; Cell Adhesion Molecules; Diabetes Mellitus, Type 1; Endothelium, Vascular; Humans; In | 1992 |
8 trials available for pentoxifylline and Peripheral Vascular Diseases
| Article | Year |
|---|---|
A randomized trial of iloprost in patients with intermittent claudication.
Topics: Administration, Oral; Aged; Double-Blind Method; Female; Humans; Iloprost; Intermittent Claudication | 2008 |
Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
Topics: Alprostadil; Arterial Occlusive Diseases; Combined Modality Therapy; Exercise Therapy; Female; Follo | 1994 |
A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly.
Topics: Aged; Aspirin; Female; Humans; Intermittent Claudication; Male; Pentoxifylline; Peripheral Vascular | 1997 |
Treatment of vascular disease caused by vibration.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Cumulative Trauma Disorders; Gases; Humans; Injections, S | 1995 |
Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease.
Topics: Administration, Oral; Aged; Arterial Occlusive Diseases; Drug Monitoring; Female; Glycosaminoglycans | 1997 |
Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial.
Topics: Administration, Oral; Combined Modality Therapy; Double-Blind Method; Exercise Therapy; Humans; Inte | 1992 |
Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.
Topics: Cross-Sectional Studies; Double-Blind Method; Female; Free Radicals; Humans; Leukocytes; Longitudina | 1991 |
Haemorheological treatment of painful sickle cell crises. Use of pentoxifylline.
Topics: Adult; Anemia, Sickle Cell; Humans; Pain; Pentoxifylline; Peripheral Vascular Diseases | 1991 |
15 other studies available for pentoxifylline and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Improvement of Ulcerations in Treatment-Resistant Chronic Scarring in a Patient with Pyoderma Gangrenosum After Improving Vascular Insufficiency, Gently Removing Necrotic Debris, and Decreasing Wound Fluid.
Topics: Adult; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Chronic Disease; Cicatrix; Clobetasol | 2018 |
In vitro effect of pentoxifylline and lisofylline on deformability and aggregation of red blood cells from healthy subjects and patients with chronic venous disease.
Topics: Adult; Cells, Cultured; Erythrocyte Aggregation; Erythrocyte Deformability; Erythrocytes; Hemorheolo | 2013 |
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Topics: Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Peripheral Vascular Diseases; Tetrazole | 2013 |
Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Topics: Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Peripheral Vascular Diseases; Tetrazole | 2013 |
The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients.
Topics: Aged; Biomechanical Phenomena; Cardiovascular Agents; Case-Control Studies; Cilostazol; Dyskinesias; | 2010 |
Peripheral artery disease: current insight into the disease and its diagnosis and management.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Cilostazol; Diagnosis, Differential; Disease Progress | 2010 |
Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
Topics: Aged; Analysis of Variance; Biomechanical Phenomena; Cilostazol; Female; Gait; Humans; Imaging, Thre | 2010 |
Selenium and the course of mild Graves' orbitopathy.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Glaucoma; Graves Ophthalmopathy; Humans; New Zealand; Pento | 2011 |
Exercise and peripheral arterial disease.
Topics: Cilostazol; Exercise Therapy; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular | 2006 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Pentoxifylline and panic attacks.
Topics: Aged; Humans; Male; Panic Disorder; Pentoxifylline; Peripheral Vascular Diseases | 1994 |
Nephroprotective mechanism(s) of pentoxifylline: reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release.
Topics: Animals; Erythrocytes; Ischemia; Kidney; Kidney Diseases; Male; Nitric Oxide; Pentoxifylline; Periph | 1996 |
A new treatment for peripheral arterial disease.
Topics: Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Platele | 2001 |
Lack of effect of pentoxifylline on red blood cell deformability.
Topics: Adult; Erythrocyte Deformability; Female; Humans; Male; Pentoxifylline; Peripheral Vascular Diseases | 1992 |
Expansion of contracted visual fields following treatment with pentoxifylline in two patients with coexistent peripheral vascular disease--case reports.
Topics: Aged; Humans; Intermittent Claudication; Ischemia; Leg; Male; Middle Aged; Pentoxifylline; Periphera | 1992 |